- Home
- BBIO vs PPC Comparison
BBIO vs PPC Comparison
Compare BBIO & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- PPC
- Stock Information
- Founded
- BBIO 2015
- PPC 1946
- Country
- BBIO United States
- PPC United States
- Employees
- BBIO N/A
- PPC N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- PPC Meat/Poultry/Fish
- Sector
- BBIO Health Care
- PPC Consumer Staples
- Exchange
- BBIO Nasdaq
- PPC Nasdaq
- Market Cap
- BBIO 9.4B
- PPC 10.5B
- IPO Year
- BBIO 2019
- PPC 1987
- Fundamental
- Price
- BBIO $51.21
- PPC $43.63
- Analyst Decision
- BBIO Strong Buy
- PPC Hold
- Analyst Count
- BBIO 16
- PPC 4
- Target Price
- BBIO $64.44
- PPC $47.50
- AVG Volume (30 Days)
- BBIO 2.2M
- PPC 1.4M
- Earning Date
- BBIO 11-11-2025
- PPC 10-29-2025
- Dividend Yield
- BBIO N/A
- PPC 19.32%
- EPS Growth
- BBIO N/A
- PPC 62.69
- EPS
- BBIO N/A
- PPC 5.19
- Revenue
- BBIO $235,812,000.00
- PPC $18,177,417,000.00
- Revenue This Year
- BBIO $115.49
- PPC $3.72
- Revenue Next Year
- BBIO $64.61
- PPC $0.72
- P/E Ratio
- BBIO N/A
- PPC $8.40
- Revenue Growth
- BBIO 7.62
- PPC 2.06
- 52 Week Low
- BBIO $21.72
- PPC $40.09
- 52 Week High
- BBIO $54.60
- PPC $57.16
- Technical
- Relative Strength Index (RSI)
- BBIO 52.92
- PPC 38.32
- Support Level
- BBIO $52.20
- PPC $41.95
- Resistance Level
- BBIO $54.60
- PPC $44.12
- Average True Range (ATR)
- BBIO 2.26
- PPC 1.08
- MACD
- BBIO -0.06
- PPC -0.11
- Stochastic Oscillator
- BBIO 56.48
- PPC 39.53
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.